Loading the section…

PMCB: financial statements from SEC — TradeAlmanac

PMCB

PharmaCyte Biotech, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/01/2026	31/10/2025	31/07/2025	31/01/2025	31/10/2024	31/07/2024
Revenue	0	0	0	0	0	0
Research and development	93,113	141,085	95,157	118,196	97,470	96,016
Selling, general and administrative	2M	1M	753,148	842,056	1M	1M
Operating expenses	2M	1M	848,305	960,252	1M	1M
Operating income	−2M	−1M	−848,305	−960,252	−1M	−1M
Net income	746,860	−7M	−8M	−3M	−1M	23M
Earnings per share	−0.17	−1.24	−1.23	−0.44	−0.39	1.90
Earnings per share, diluted	−0.17	−1.24	−1.23	−0.44	−0.39	1.90
Weighted average shares	9M	7M	7M	7M	8M	8M
Weighted average shares, diluted	9M	7M	7M	7M	8M	8M

Balance sheet

Metric	31/01/2026	31/10/2025	31/07/2025	30/04/2025	31/01/2025	31/10/2024	31/07/2024	30/04/2024
Cash and equivalents	20M	15M	13M	15M	16M	21M	33M	50M
Short-term investments	372,251	201,190	261,853

Cash flow

Metric	31/07/2025	31/07/2024
Operating cash flow	−2M	−373,297
Share-based compensation	60,492	222,677
Investing cash flow	0	−7M
Share buybacks	0	742,179
Financing cash flow	0	−10M

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator